A number of preclinical and clinical investigations are underway to target the CD47/SIRPα axis for cancer therapy, including examination of the synergistic effect with other anti-tumor agents such as rituximab (anti-CD20 antibody), cetuximab (an inhibitor of EGFR), and trastuzumab (an inhibitor of human epidermal growth factor receptor 2, HER2) (81). Here, SIRPA is linked to neoplasm.